glp 1 coverage 2026 GLP-1 Drugs, Digital Health & Obesity Trends in What You Need to Know
Description
43 Therefore, discontinuation of treatmentprimarily due to cost and access limitationsremains the major barrier to the widespread and sustainable use of these agents
In clinical medicine, microdosing GLP-1s is not a formal category
Further, it is worth highlighting that survodutide is likely to drive the market in the near future
The difference is not the medication itself, but how its delivered and absorbed by the body
A patch can act like a daily reminder to eat with intention, and that behavioral nudge can be real
National Academy of Medicine
